Individualized immunosuppression in transplant patients: potential role of pharmacogenetics

References

• LodhiSALambKEMeier-KriescheHUSolid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term successAm J Transplant2011111226123521564524
   PubMed Web of Science ®Google Scholar
• HanawayMJWoodleESMulgaonkarSAlemtuzumab induction in renal transplantationN Engl J Med20113641909191921591943
   PubMed Web of Science ®Google Scholar
• TiedeIFritzGStrandSCD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytesJ Clin Invest20031111133114512697733
   PubMed Web of Science ®Google Scholar
• SchackeHDockeWDAsadullahKMechanisms involved in the side effects of glucocorticoidsPharmacol Ther200296234312441176
   PubMed Web of Science ®Google Scholar
• LuanFLSteffickDEGadegbekuCNormanSPWolfeROjoAOGraft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppressionAm J Transplant2009916016818976304
   PubMed Web of Science ®Google Scholar
• VincentiFSchenaFPParaskevasSHauserIAWalkerRGGrinyoJA randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipientsAm J Transplant2008830731618211506
   PubMed Web of Science ®Google Scholar
• Smak GregoorPJde SevauxRGLigtenbergGWithdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter studyJ Am Soc Nephrol2002131365137311961025
   PubMed Web of Science ®Google Scholar
• RostaingLCantarovichDMouradGCorticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantationTransplantation20057980781415818323
   PubMed Web of Science ®Google Scholar
• WoodleESFirstMRPirschJShihabFGaberAOVanVPA prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapyAnn Surg200824856457718936569
   PubMed Web of Science ®Google Scholar
• KumarMSHeifetsMMoritzMJSafety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three yearsTransplantation20068183283916570004
   PubMed Web of Science ®Google Scholar
• ArnolMde MattosAMChungJSPratherJCMittalhenkleANormanDJLate steroid withdrawal and cardiovascular events in kidney transplant recipientsTransplantation2008861844184819104432
   PubMed Web of Science ®Google Scholar
• RikeAHMogilishettyGAllowayRRCardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroidsClin Transplant20082222923518339144
   PubMed Web of Science ®Google Scholar
• European Multicentre Trial GroupCyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trialLancet198329869896138592
   PubMed Web of Science ®Google Scholar
• NaesensMKuypersDRSarwalMCalcineurin inhibitor nephrotoxicityClin J Am Soc Nephrol2009448150819218475
   PubMed Web of Science ®Google Scholar
• RowshaniATScholtenEMBemelmanFNo difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one yearJ Am Soc Nephrol200617130531216306168
   PubMed Web of Science ®Google Scholar
• NankivellBJBorrowsRJFungCLO’ConnellPJChapmanJRAllenRDCalcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histologyTransplantation20047855756515446315
   PubMed Web of Science ®Google Scholar
• SnanoudjRRoyalVElieCSpecificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapyAm J Transplant2011112635264621883915
   PubMed Web of Science ®Google Scholar
• EkbergHGrinyoJNashanBCyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR StudyAm J Transplant2007756057017229079
   PubMed Web of Science ®Google Scholar
• WebsterACWoodroffeRCTaylorRSChapmanJRCraigJCTacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial dataBMJ200533181016157605
   PubMed Web of Science ®Google Scholar
• ArtzMABootsJMLigtenbergGImproved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimusJ Am Soc Nephrol2003141880188812819249
   PubMed Web of Science ®Google Scholar
• SarnakMJLeveyASSchoolwerthACKidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and PreventionCirculation20031082154216914581387
   PubMed Web of Science ®Google Scholar
• EkbergHTedesco-SilvaHDemirbasAReduced exposure to calcineurin inhibitors in renal transplantationN Engl J Med20073572562257518094377
   PubMed Web of Science ®Google Scholar
• BakkerRCHollanderAAMallatMJBruijnJAPaulLCde FijterJWConversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathyKidney Int2003641027103412911553
   PubMed Web of Science ®Google Scholar
• JossNRodgerRSMcMillanMAJunorBJRandomized study comparing cyclosporine with azathioprine one year after renal transplantation-15-year outcome dataTransplantation20078358258717353778
   PubMed Web of Science ®Google Scholar
• MacDonaldAScarolaJBurkeJTZimmermanJJClinical pharmacokinetics and therapeutic drug monitoring of sirolimusClin Ther.200022Suppl BB101B12110823378
   PubMed Web of Science ®Google Scholar
• KahanBDWongRLCarterCA phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipientsTransplantation1999681100110610551636
   PubMed Web of Science ®Google Scholar
• DeanPGLundWJLarsonTSWound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimusTransplantation2004771555156115239621
   PubMed Web of Science ®Google Scholar
• LangerRMKahanBDIncidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipientsTransplantation20027480480812364859
   PubMed Web of Science ®Google Scholar
• PascualMTheruvathTKawaiTTolkoff-RubinNCosimiABStrategies to improve long-term outcomes after renal transplantationN Engl J Med200234658059011856798
   PubMed Web of Science ®Google Scholar
• AnglicheauDPalletNRabantMRole of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interactionKidney Int2006701019102516837925
   PubMed Web of Science ®Google Scholar
• CampistolJMErisJOberbauerRSirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantationJ Am Soc Nephrol20061758158916434506
   PubMed Web of Science ®Google Scholar
• EkbalNJHoltDWMacpheeIAPharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patientsPharmacogenomics2008958559618466104
   PubMed Web of Science ®Google Scholar
• HalloranPMathewTTomlanovichSGrothCHooftmanLBarkerCMycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study GroupsTransplantation19976339479000658
   PubMed Web of Science ®Google Scholar
• OjoAOMeier-KriescheHUHansonJAMycophenolate mofetil reduces late renal allograft loss independent of acute rejectionTransplantation2000692405240910868649
   PubMed Web of Science ®Google Scholar
• VincentiFCharpentierBVanrenterghemYA phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)Am J Transplant20101053554620415897
   PubMed Web of Science ®Google Scholar
• ClatworthyMRTargeting B cells and antibody in transplantationAm J Transplant2011111359136721668625
   PubMed Web of Science ®Google Scholar
• WalshRCBraileyPGirnitaAEarly and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibitionTransplantation2011911218122621617586
   PubMed Web of Science ®Google Scholar
• StegallMDDiwanTRaghavaiahSTerminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipientsAm J Transplant2011112405241321942930
   PubMed Web of Science ®Google Scholar
• ChapmanJRO’ConnellPJNankivellBJChronic renal allograft dysfunctionJ Am Soc Nephrol2005163015302616120819
   PubMed Web of Science ®Google Scholar
• SagooPPeruchaESawitzkiBDevelopment of a cross-platform biomarker signature to detect renal transplant tolerance in humansJ Clin Invest20101201848186120501943
   PubMed Web of Science ®Google Scholar
• NewellKAAsareAKirkADIdentification of a B cell signature associated with renal transplant tolerance in humansJ Clin Invest20101201836184720501946
   PubMed Web of Science ®Google Scholar
• SommererCZeierMMeuerSGieseTIndividualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipientsTransplantation2010891417142320463649
   PubMed Web of Science ®Google Scholar
• GlanderPSommererCArnsWPharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patientsClin J Am Soc Nephrol2010550351120150450
   PubMed Web of Science ®Google Scholar
• BremerSMandlaRVetheNTExpression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppressionTransplantation200885556118192912
   PubMed Web of Science ®Google Scholar
• BohlerTNoltingJKamarNValidation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humansTher Drug Monit200729778617304154
   PubMed Web of Science ®Google Scholar
• KowalskiRJPostDRMannonRBAssessing relative risks of infection and rejection: a meta-analysis using an immune function assayTransplantation20068266366816969290
   PubMed Web of Science ®Google Scholar
• HoltDWTherapeutic drug monitoring of immunosuppressive drugs in kidney transplantationCurr Opin Nephrol Hypertens20021165766312394613
   PubMed Web of Science ®Google Scholar
• ClaseCMMahalatiKKiberdBAAdequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profilingAm J Transplant2002278979512243501
   PubMed Web of Science ®Google Scholar
• UndreNAvan HoofJChristiaansMLow systemic exposure to tacrolimus correlates with acute rejectionTransplant Proc19993129629810083114
   PubMed Web of Science ®Google Scholar
• van GelderTHilbrandsLBVanrenterghemYA randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantationTransplantation19996826126610440399
   PubMed Web of Science ®Google Scholar
• EvansWEThiopurine S-methyltransferase: a genetic polymorphism that affects a small number of drugs in a big wayPharmacogenetics20021242142312172209
   PubMedGoogle Scholar
• StaatzCETettSEClinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantationClin Pharmacokinet20044362365315244495
   PubMed Web of Science ®Google Scholar
• StaatzCETettSEPharmacokinetic considerations relating to tacrolimus dosing in the elderlyDrugs Aging20052254155716038570
   PubMed Web of Science ®Google Scholar
• VadivelNGargAHoltDWChangRWMacpheeIATacrolimus dose in black renal transplant recipientsTransplantation20078399799917460575
   PubMed Web of Science ®Google Scholar
• MacPheeIAMFredericksSTaiTTacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirementTransplantation2002741486148912490779
   PubMed Web of Science ®Google Scholar
• NgFLHoltDWMacpheeIAPharmacogenetics as a tool for optimising drug therapy in solid-organ transplantationExpert Opin Pharmacother200782045205817714059
   PubMed Web of Science ®Google Scholar
• MacpheeIAUse of pharmacogenetics to optimize immunosuppressive therapyTher Drug Monit20103226126420431509
   PubMed Web of Science ®Google Scholar
• HesselinkDAvan SchaikRHvan AgterenMCYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipientsPharmacogenet Genomics20081833934818334918
   PubMed Web of Science ®Google Scholar
• ThervetELoriotMABarbierSOptimization of initial tacrolimus dose using pharmacogenetic testingClin Pharmacol Ther20108772172620393454
   PubMed Web of Science ®Google Scholar
• ElensLBouamarRHesselinkDAA new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipientsClin Chem2011571574158321903774
   PubMed Web of Science ®Google Scholar
• de JongeHMetalidisCNaesensMLambrechtsDKuypersDRThe P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipientsPharmacogenomics2011121281129121770725
   PubMed Web of Science ®Google Scholar
• PasseyCBirnbaumAKBrundageRCOettingWSIsraniAKJacobsonPADosing equation for tacrolimus using genetic variants and clinical factorsBr J Clin Pharmacol20117294895721671989
   PubMed Web of Science ®Google Scholar
• LambaJLambaVSchuetzEGenetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogeneticsCurr Drug Metab2005636938316101575
   PubMed Web of Science ®Google Scholar
• PressRRPloegerBAdenHJExplaining variability in ciclosporin exposure in adult kidney transplant recipientsEur J Clin Pharmacol20106657959020354687
   PubMed Web of Science ®Google Scholar
• FredericksSJorgaAMacPheeIAMMulti-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurementsClin Transplant20072125225717425754
   PubMed Web of Science ®Google Scholar
• ElensLvan SchaikRHPaninNEffect of a new functional CYP3A4 polymorphism on calcineurin inhibitors dose requirements and trough blood levels in stable renal transplant patientsPharmacogenomics2011121383139621902502
   PubMed Web of Science ®Google Scholar
• AnglicheauDLe CorreDLechatonSConsequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapyAm J Transplant2005559560315707415
   PubMed Web of Science ®Google Scholar
• Le MeurYDjebliNSzelagJCCYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipientsClin Pharmacol Ther200680516016815317
   PubMed Web of Science ®Google Scholar
• MiaoLYHuangCRHouJQQianMYAssociation study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipientsBiopharm Drug Dispos2007291517941052
   PubMed Web of Science ®Google Scholar
• PicardNRouguieg-MalkiKKamarNRostaingLMarquetPCYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipientsTransplantation20119165265621389905
   PubMed Web of Science ®Google Scholar
• van SchaikRHvanAMde FijterJWUGT1A9-275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patientsClin Pharmacol Ther20098631932719494809
   PubMed Web of Science ®Google Scholar
• WangJYangJWZeeviAIMPDH1 gene polymorphisms and association with acute rejection in renal transplant patientsClin Pharmacol Ther20078371171717851563
   PubMed Web of Science ®Google Scholar
• CrettolSVenetzJPFontanaMInfluence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipientsPharmacogenet Genomics20081830731518334915
   PubMed Web of Science ®Google Scholar
• CapronAMouradMdeMMCYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantationPharmacogenomics20101170371420415563
   PubMed Web of Science ®Google Scholar